Laxmi Organic Industries (LXCHEM) Q1 24/25 earnings summary

Executive summary

• Strategy centers on cost and technology leadership, aiming for a top 5 global position in all segments, with strong customer partnerships and diversified end-market exposure.

• Achieved sequential and year-over-year growth in Q1 FY25, excluding one-off effects and despite scheduled plant maintenance in Essentials.

• Operational excellence and improved product mix in Specialties contributed positively.

• Key assets at the Fluoro-intermediates site at Lote are operational, with product samples dispatched to customers.

• Unaudited standalone and consolidated financial results for Q1 FY25 were approved with an unmodified opinion from statutory auditors.

Financial highlights

• Standalone revenue for Q1 FY25 was INR 7,296 million, up 4% year-on-year; standalone net profit was INR 463.11 million, up from INR 379.42 million in Q1 FY24.

• Standalone EBITDA at INR 941 million, up 15% year-on-year; PBT at INR 702.84 million, up from INR 550.44 million in Q1 FY24.

• Consolidated revenue for Q1 FY25 was INR 7,301 million, flat year-on-year; consolidated net profit was INR 343.51 million, down from INR 383.29 million in Q1 FY24.

• Gross margin for Q1 FY25 was 36.6% (consolidated); EBITDA margin at 11.4%; PAT margin at 4.7%.

• Cash flow from operations at INR 80 crore for the quarter.

Outlook and guidance

• Ambition to double revenues and triple EBITDA by FY2028, with a CapEx plan of INR 11,000 million from FY2024 to FY2028.

• Revenue from Dahej facility expected to start in FY2026, with peak revenues by FY2028.

• Specialties segment to maintain over 20% revenue from new products; Fluoro assets expected to contribute from FY25.

• Conservative margin assumptions for essentials, with potential upside from new specialty products.